The rules that once governed pharma launches are slowly breaking down. Companies that once planned launches and invested with confidence now face uncertainty in evidence generation, regulatory approvals and global launch sequences. Yet, the industry is heading into one of its busiest launch periods in recent years.
Challenges
For pharma leaders, this creates a real tension: launches require more upfront commitment than ever, and early investments are just as risky. That’s where developing a strong pharma pricing strategy becomes critical. But first, it’s important to identify the uncertainties and risks involved:
Regulatory uncertainties
The Food and Drug Administration (FDA) has rejected and delayed approval of several rare disease drugs due to its changing evidentiary requirements. These changes entail that instead of two trials, rare disease drug approvals will depend on the overall survival rate and a single pivotal trial.
Evolving global pricing dynamics
The most favored nation (MFN) prices and tariffs have changed the dynamics of where and how manufacturers are allowed to launch drugs. Changes in U.S. net pricing have also squeezed the profits of middlemen and put global pricing under pressure.
Preparing for successful launch
Speed without shortcuts
One of the biggest drains on launch timelines is the sheer volume of customer-facing content that needs to go through medical, legal, and regulatory (MLR) review. At the same time, hiring, onboarding and training a team is both time-consuming and resource-intensive. That’s time not spent planning the launch. Leading companies are using artificial intelligence (AI) to streamline MLR review and move from week-long launch cycles to days, keeping launches on track without cutting corners.
Build durable capabilities
The other important shift is building durable infrastructure. Current launches often follow a framework that speeds things up in the short term but isn’t built to last. Most pharma organizations rebuild their launch infrastructure from scratch every time: new dashboards, new trackers, new playbooks. It works, but it’s slow and expensive. Instead, leaders should take a smarter approach: building systems paired with market access solutions and a team of launch specialists who bring hard-won expertise from one product to the next.
In an environment where launches are constantly being tested, the companies that win aren’t the ones with the biggest launch budgets. They’re the ones that move faster and turn launches into competitive advantage.
